Key result
Targeted SERCA2a gene therapy shows promise as a safe new treatment approach for CHF.
Why the study?
Despite steady gains with conventional treatments, congestive heart failure remains a major cause of morbidity and mortality, creating a critical need to explore new therapeutic approaches such as targeted gene transfer.
Answers are grounded in this paper and cite their sources.
Gene therapy targeting mechanisms like SERCA2a is emerging as a potential therapeutic strategy for congestive heart failure.
Congestive heart failure is a major cause of morbidity and mortality in the US. While progress in conventional treatments is making steady and incremental gains to reduce heart failure mortality, there is a critical need to explore new therapeutic approaches. Gene therapy was initially applied in the clinical setting for inherited monogenic disorders. It is now apparent that gene therapy has broader potential that also includes acquired polygenic diseases, such as congestive heart failure. Recent advances in understanding of the molecular basis of myocardial dysfunction, together with the evolution of increasingly efficient gene transfer technology, has placed heart failure within reach of gene-based therapy. Furthermore, the recent successful and safe completion of a phase 2 trial targeting the sarcoplasmic reticulum calcium ATPase pump (SERCA2a) along with the start of more recent phase 1 trials usher a new era for gene therapy for the treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Kawase et al. (2011) conducted a review in Congestive heart failure. Gene therapy (targeting SERCA2a) was evaluated. Targeted gene therapy, including a recently completed phase 2 trial targeting the SERCA2a pump, represents a promising and safe new therapeutic approach for the treatment of congestive heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: